Literature DB >> 21847070

Synthesis of new riminophenazines with pyrimidine and pyrazine substitution at the 2-N position.

Gang Zhang1, Hao Zhang, Xiaojian Wang, Chun Li, Haihong Huang, Dali Yin.   

Abstract

New riminophenazines with pyrimidine and pyrazine substituents at the 2-position were successfully synthesized. The key step is the 2-N-arylation of riminophenazines with pyrimidine and pyrazine. The optimized reaction conditions involve the use of a Pd₂(dba)₃/DPPF/Cs₂CO₃/toluene combination.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21847070      PMCID: PMC6264567          DOI: 10.3390/molecules16086985

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


1. Introduction

Riminophenazines such as clofazimine (Figure 1) are of great interest to many medicinal chemists due to their various biological activities in the anti-mycobacterial [1,2], anti-tumor [3] and anti-inflammatory areas [4,5,6], especially for multidrug resistant tuberculosis (MDR-TB) [7]. In our ongoing search for novel antituberculotic riminophenazines, a series of new compounds were designed, including riminophenazines with heteroaromatic substituents at the 2-N position.
Figure 1

Chemical structures of clofazimine and known riminophenazine derivatives.

There are generally two methods for the preparation of riminophenazines. Condensation of two molecules of N-chlorophenyl-1,2-diaminobenzene by oxidation with FeCl3 to form the tricyclic core of a riminophenazine gives the same substituents on the 2-N-phenyl and 5-phenyl rings [8]. For the compounds with different substituents in the 2-N and 5 positions, a method developed by Andre Girard [9] allows step by step introduction of different substituted anilines into the molecules. The synthesis of riminophenazine with peripheral heteroaromatic substituents in the molecule has not been reported. Herein we report the synthesis of new riminophenazines with pyrimidine and pyrazine substitutions at the 2-N position. Chemical structures of clofazimine and known riminophenazine derivatives.

2. Results and Discussion

An initial investigation of the synthesis of target compounds followed known procedures [9] (Scheme 1). Unfortunately, the key intermediate 1 could not be converted into the desired iminophenazine 2. Only a black tar was obtained, possibly due to instability of the intermediates with pyrimidine substituents.
Scheme 1

Cyclization of riminophenazine core with pyrimidine substituent.

Cyclization of riminophenazine core with pyrimidine substituent. To overcome the difficulties in the key cyclization step of the synthesis, the synthetic procedures were modified and the attachment of heteroaromatic substituents was moved to the last step of the synthesis to avoid decomposition of the intermediates Scheme 2). Thus, the synthesis was started from 1,5-difluoro-2,4-dinitrobenzene (4), which is more reactive towards amine substitution. The two fluoro groups of compound 4 was subsequently replaced by N-(4-chlorophenyl)benzenediamine (3) and ammonia to give the key intermediate 6. The dinitro groups of 6 were reduced either by catalytic hydrogenation over Pd-C or by zinc powder reduction and the intermediate 7, without isolation, was exposed to air and cyclized to form the desired riminophenazin core 8 with an amino group pending in the 2-position. Compound 9 was obtained by displacement of the imino moiety with isopropylamine in a sealed bomb. When the palladium catalyzed N-arylation, better known as the Buchwald-Hartwig reaction [10], was applied to the 2-N arylation of 9 with 2-bromopyrimidine under the usual reaction conditions, none of the desired product was formed. After screening of condition variables, such as Pd catalyst, ligand, base, and solvent, a combination suitable for the N-arylation of 9 with 2-bromo-pyrimidine was found (Entry 7). The target compound 11a was thus obtained in 95.8% yield.
Scheme 2

New synthetic route for riminophenazines with heteroaromatic substituents.

New synthetic route for riminophenazines with heteroaromatic substituents. When the optimized combination was used for the coupling of 9 with 2-bromopyrazine, the desired product 11b was also obtained in 95.2% yield. Optimization of N-arylation of riminophenazines a,b. a Reaction conditions: 9 (1.0 equiv, 0.20mmol), 2-bromopyrimidine (1.5 equiv), catalyst (2 mol %), ligand (8 mol %), base (1.5 equiv); b The product were purified by flash silica gel chromatography; c All yields are reported for isolated and purified products; d IPr•HCl = 1,3-bis(2,6-diisopropylphenyl)-imidazolium chloride.

3. Experimental

3.1. General

All chemicals and reagents were purchased from commercial sources and used without further purification. All reactions were monitored by TLC. Chromatography refers to open column chromatography (CC) on silica gel (SiO2; 160–200 mesh). Melting points were determined on a Yanaco micrometer and are uncorrected. 1H- and 13C-NMR spectra were recorded on Varian Mercury 300 MHz and 400 MHz spectrometers; chemical shifts δ in ppm rel. to TMS or DMSO-d6 as internal standards. High resolution mass spectra were recorded on an Agilent LC/MSD TOF spectrometer. N-(4-Chlorophenyl)-N’-(5-fluoro-2,4-dinitrophenyl)benzene-1,2-diamine (5): 2-(4-Chloroanilino)-aniline (20 mmol) and triethylamine (3 mL) were added to a solution of 1,5-difluoro-2,4-dinitrobenzene (20 mmol) in methanol (100 mL). The reaction mixture was stirred at rt for 4 h, then filtered, and the cake was washed with methanol and dried to give compound 5 in 85% yield. mp: 209–211 °C, 1H-NMR (300 MHz, DMSO-d6): δ 9.97 (s, 1H), 8.88 (d, J = 8.1 Hz, 1H), 7.89 (s, 1H), 7.31 (m, 3H), 7.22 (d, J = 8.1 Hz, 2H), 7.06 (m, 1H), 6.97 (d, J = 8.1 Hz, 2H), 6.47 (d, J = 14.1 Hz, 1H); 13C-NMR (100 MHz, DMSO-d) δ: 158.6 (d, J = 249.9 Hz), 148.2, 148.1, 141.7, 139.1, 128.8, 128.2, 126.8, 126.4, 125.8, 125.7, 123.9, 121.6, 119.5, 118.8, 103.1 (d, J = 27.4 Hz); HRMS (ESI-TOF+): m/z [M+H]+ calcd. for C18H13ClFN4O4: 403.0604; found: 403.0608. N-(5-Amino-2,4-dinitrophenyl)-N’-(4-chlorophenyl)benzene-1,2-diamine (6): A mixture of compound 5 (15 mmol), 25% ammonia (10 mL) and THF (20 mL) was heated to 70 °C for 12 h in a sealed bomb, then about 20 mL of THF was removed under reduced pressure. After being cooled to rt. the suspension was filtered, and the cake was washed with CH2Cl2 to give compound 6 in 98% yield. mp: 248–249 °C, 1H-NMR (300 MHz, DMSO-d6): δ 8.92 (s, 1H), 7.77 (m, 3H), 7.28 (m, 5H), 7.06 (m, 1H), 7.00 (m, 2H), 6.15 (s, 1H), 5.76 (s, 1H); 13C-NMR (100 MHz, DMSO-d) δ: 149.6, 146.3, 144.3, 142.4, 138.9, 128.7, 127.9, 127.8, 127.6, 125.0, 123.9, 123.6, 121.7, 119.3, 118.9, 96.8; HRMS (ESI-TOF+): m/z [M+H]+ calcd. for C18H15ClN5O4: 400.0807; found: 400.0806. 5-(4-Chlorophenyl)-3-imino-3,5-dihydrophenazin-2-amine (8): Compound 6 (10 mmol) was suspended in anhydrous methanol (100 mL). The mixture was hydrogenated at 40 psi over 10% Pd-C (0.4 g). Then the Pd-C was removed by filtration. The filtrate containing compound 7 was stirred at rt in contact with air overnight. The solid formed was filtered, washed with methanol, and dried to give compound 8 in 81% yield. mp: 238–240 °C, 1H-NMR (300 MHz, DMSO-d6): δ 7.86 (d, J = 8.7 Hz, 2H), 7.76 (m, 1H), 7.59 (d, J = 8.7 Hz, 2H), 7.31 (m, 2H), 6.78 (brs, 2H), 6.57 (m, 1H), 6.49 (s, 1H), 5.45 (s, 1H); 13C-NMR (100 MHz, DMSO-d) δ: 149.8, 149.3, 148.1, 136.0, 135.6, 134.5, 133.2, 131.4, 130.8, 130.5, 128.2, 127.7, 123.2, 114.3, 99.8, 96.0; HRMS (ESI-TOF+): m/z [M+H]+ calcd. for C18H14ClN4: 321.0902; found: 321.0894. 5-(4-Chlorophenyl)-3-(isopropylimino)-3,5-dihydrophenazin-2-aminee (9): Compound 8 (5 mmol), isopropylamine (25 mmol) and dioxane (100 mL) were mixed in a sealed bomb and stirred at 110 °C for 24 h. After being cooled to rt, water was added, and the mixture was suction filtered, washed with water and dried to give a dark solid. The solid was purified by flash column chromatography (EtOAc/hexane 1:2) to give compound 9 in 82% yield. mp: 234–235 °C, 1H-NMR (300 MHz, DMSO-d6): δ 7.84 (d, J = 8.4 Hz, 2H), 7.59 (m, 1H), 7.55 (d, J = 8.4 Hz, 2H), 7.14 (m, 2H), 6.39 (m, 3H), 6.27 (s, 1H), 5.11 (s, 1H), 3.29 (m, 1H), 0.98 (d, J = 6.3 Hz, 6H); 13C-NMR (100 MHz, DMSO-d) δ: 150.7, 150.3, 149.5, 136.2, 135.3, 134.2, 133.9, 131.5, 131.0, 130.7, 127.2, 126.6, 122.4, 113.8, 97.9, 88.2, 48.8, 23.4; HRMS (ESI-TOF+): m/z [M+H]+ calcd. for C21H20ClN4: 363.1371; found: 363.1367. 5-(4-Chlorophenyl)-3-(isopropylimino)-N-pyrimidin-2-yl-3,5-dihydrophenazin-2-amine (11a): Under an atmosphere of N2, toluene (50 mL), 2-bromopyrimidine (3 mmol), compound 9 (2 mmol), Pd2(dba)3 (0.1 mmol), DPPF (0.4 mmol) and Cs2CO3 (3 mmol) were subsequently added to a two-necked round-bottomed flask with a reflux condenser. The mixture was refluxed for 2 h, allowed to cool to rt, and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by flash silica gel chromatography (EtOAc/hexane 1:2) to give compound 11a in 95.8% yield. mp: 232–235 °C, 1H-NMR (300 MHz, CDCl3) δ: 9.76 (1H, br s), 8.56 (2H, d, J = 4.5 Hz), 8.49 (s, 1H), 7.77 (1H, d, J = 6.9 Hz), 7.71 (2H, m), 7.32 (2H, m), 7.17 (2H, m), 6.83 (1H, m), 6.44 (1H, d, J = 6.9 Hz), 5.28 (1H, s), 3.47 (1H, m), 1.10 (6H, d, J = 6.0 Hz); 13C-NMR (100 MHz, CDCl3) δ: 159.3, 157.9, 151.8, 150.1, 140.2, 136.0, 135.7, 135.0, 132.0, 131.7, 130.5, 128.8, 128.3, 122.8, 113.7, 113.5, 108.4, 89.0, 49.4, 23.6; HRMS (ESI-TOF+): m/z [M+H]+ calcd. for C25H22ClN6: 441.1589; found: 441.1585. 5-(4-Chlorophenyl)-3-(isopropylimino)-N-pyrazin-2-yl-3,5-dihydrophenazin-2-amine (11b): Under an atmosphere of N2, toluene (50 mL), 2-bromopyrazine (3 mmol), compound 9 (2 mmol), Pd2(dba)3 (0.1 mmol), DPPF (0.4 mmol) and Cs2CO3 (3 mmol) were added in turn to a two-necked round-bottomed flask with a reflux condenser. The mixture was refluxed for 2 h, allowed to cool, and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by flash silica gel chromatography (EtOAc/hexane 1:2) to give compound 11b in 95.2% yield. mp: 228–230 °C, 1H-NMR (300 MHz, CDCl3) δ: 8.43 (1H, s), 8.29 (2H, m), 8.05 (1H, d, J = 2.4 Hz), 7.77 (1H, d, J = 6.9 Hz), 7.71 (2H, d, J = 8.1 Hz), 7.31 (2H, d, J = 8.1 Hz), 7.17 (2H, m), 6.45 (1H, d, J = 7.8 Hz), 5.28 (1H, s), 3.47 (1H, m), 1.11 (6H, d, J = 6.3 Hz); 13C-NMR (100 MHz, CDCl3) δ: 151.4, 151.0, 150.4, 141.6, 140.0, 136.4, 135.9, 135.8, 135.5, 135.1, 131.7, 130.4, 128.9, 128.4, 123.0, 113.8, 107.5, 88.9, 49.3, 23.6; HRMS (ESI-TOF+): m/z [M+H]+ calcd. for C25H22ClN6: 441.1589; found: 441.1581.

4. Conclusions

In summary, we have successfully synthesized riminophenazines with a pyrimidine or pyrazine substituent on the molecule. To our knowledge, this is the first synthesis of heteroaromatic-substituted riminophenazine derivatives and it should prove valuable for the study of the chemistry and biological activity of this class of compounds.
Table 1

Optimization of N-arylation of riminophenazines a,b.

EntryCatalystLigandBaseSolventT(°C)/Time(h)Yield(%) c
1 [11]Pd2(dba)3IPr·HCl dt-BuOK1,4-dioxane100/240
2 [12]PdCl2P(o-tolyl)3t-BuOKxylene110/240
3PdCl2DPPFCs2CO3toluene110/857.6
4Pd(OAc)2DPPFCs2CO3THF68/80
5Pd(OAc)2DPPFCs2CO3toluene70/2425.1
6Pd(OAc)2DPPFCs2CO3toluene110/831.3
7Pd2(dba)3DPPFCs2CO3toluene110/295.8
8 [13]Pd2(dba)3rac-BINAPCs2CO3toluene110/1288.9

a Reaction conditions: 9 (1.0 equiv, 0.20mmol), 2-bromopyrimidine (1.5 equiv), catalyst (2 mol %), ligand (8 mol %), base (1.5 equiv); b The product were purified by flash silica gel chromatography; c All yields are reported for isolated and purified products; d IPr•HCl = 1,3-bis(2,6-diisopropylphenyl)-imidazolium chloride.

  10 in total

1.  Treatment of pyoderma gangrenosum with clofazimine.

Authors:  B Kaplan; H Trau; E Sofer; A Feinstein; M Schewach-Millet
Journal:  Int J Dermatol       Date:  1992-08       Impact factor: 2.736

2.  "B 663" in the treatment of leprosy. Preliminary report of a pilot trial.

Authors:  S G BROWNE; L M HOGERZEIL
Journal:  Lepr Rev       Date:  1962-01       Impact factor: 0.537

3.  Anti-tubercular activity of oxidation products of substituted o-phenylene diamines.

Authors:  V C BARRY; J G BELTON
Journal:  Nature       Date:  1948-10-16       Impact factor: 49.962

4.  Efficient methods for the synthesis of 2-hydroxyphenazine based on the Pd-catalyzed N-arylation of aryl bromides.

Authors:  Mario Tietze; Alberto Iglesias; Elena Merisor; Jürgen Conrad; Iris Klaiber; Uwe Beifuss
Journal:  Org Lett       Date:  2005-04-14       Impact factor: 6.005

5.  A treatment of corticosteroid-dependent lepromatous patients in persistent erythema nodosum leprosum. A clinical evaluation of G.30320 (B663).

Authors:  F M Imkamp
Journal:  Lepr Rev       Date:  1968-07       Impact factor: 0.537

6.  Clofazimine in the treatment of discoid lupus erythematosus.

Authors:  J P Mackey; J Barnes
Journal:  Br J Dermatol       Date:  1974-07       Impact factor: 9.302

Review 7.  New antimycobacterial agents.

Authors:  W W Yew; C H Chau
Journal:  Monaldi Arch Chest Dis       Date:  1996-10

8.  Amination reactions of aryl halides with nitrogen-containing reagents mediated by palladium/imidazolium salt systems.

Authors:  G A Grasa; M S Viciu; J Huang; S P Nolan
Journal:  J Org Chem       Date:  2001-11-16       Impact factor: 4.354

9.  Palladium-catalyzed coupling of ammonia with aryl chlorides, bromides, iodides, and sulfonates: a general method for the preparation of primary arylamines.

Authors:  Giang D Vo; John F Hartwig
Journal:  J Am Chem Soc       Date:  2009-08-12       Impact factor: 15.419

10.  The riminophenazine agents clofazimine and B669 inhibit the proliferation of cancer cell lines in vitro by phospholipase A2-mediated oxidative and nonoxidative mechanisms.

Authors:  C E Van Rensburg; A M Van Staden; R Anderson
Journal:  Cancer Res       Date:  1993-01-15       Impact factor: 12.701

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.